LivaNova (NASDAQ:LIVN) Earns “Buy” Rating from Needham & Company LLC

LivaNova (NASDAQ:LIVN)‘s stock had its “buy” rating reiterated by equities research analysts at Needham & Company LLC in a research report issued on Monday,Benzinga reports. They presently have a $64.00 price target on the stock. Needham & Company LLC’s price target points to a potential upside of 63.10% from the company’s current price.

Other equities research analysts have also issued reports about the company. Wolfe Research lowered LivaNova from an “outperform” rating to a “peer perform” rating in a research report on Wednesday, February 26th. Barclays dropped their target price on LivaNova from $58.00 to $56.00 and set an “equal weight” rating on the stock in a research report on Friday, March 7th. StockNews.com lowered LivaNova from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, February 26th. Stifel Nicolaus lowered their price target on LivaNova from $72.00 to $60.00 and set a “buy” rating on the stock in a report on Wednesday, February 26th. Finally, The Goldman Sachs Group lowered their price target on LivaNova from $64.00 to $55.00 and set a “buy” rating on the stock in a report on Monday, March 3rd. Two equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, LivaNova presently has a consensus rating of “Moderate Buy” and a consensus price target of $61.17.

LivaNova Stock Performance

Shares of LIVN opened at $39.24 on Monday. The business’s fifty day moving average price is $46.00 and its 200 day moving average price is $49.07. LivaNova has a 12-month low of $36.85 and a 12-month high of $64.47. The stock has a market capitalization of $2.13 billion, a PE ratio of 93.43 and a beta of 1.10. The company has a debt-to-equity ratio of 0.46, a current ratio of 3.37 and a quick ratio of 2.87.

Institutional Investors Weigh In On LivaNova

Several large investors have recently made changes to their positions in the company. Russell Investments Group Ltd. grew its stake in shares of LivaNova by 17.1% in the 4th quarter. Russell Investments Group Ltd. now owns 1,502 shares of the company’s stock valued at $70,000 after buying an additional 219 shares in the last quarter. Summit Investment Advisors Inc. grew its stake in shares of LivaNova by 1.7% in the 4th quarter. Summit Investment Advisors Inc. now owns 16,846 shares of the company’s stock valued at $780,000 after buying an additional 289 shares in the last quarter. Atria Investments Inc grew its stake in shares of LivaNova by 6.2% in the 3rd quarter. Atria Investments Inc now owns 5,653 shares of the company’s stock valued at $297,000 after buying an additional 331 shares in the last quarter. Xponance Inc. grew its stake in shares of LivaNova by 6.1% in the 4th quarter. Xponance Inc. now owns 7,762 shares of the company’s stock valued at $359,000 after buying an additional 445 shares in the last quarter. Finally, Mariner LLC grew its stake in shares of LivaNova by 8.4% in the 4th quarter. Mariner LLC now owns 5,741 shares of the company’s stock valued at $266,000 after buying an additional 446 shares in the last quarter. Institutional investors own 97.64% of the company’s stock.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.